Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Location: United States, New Jersey, Plainsboro Township
Member count: 51-200
Phone: +1 609-452-9813
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 08.06.2018 | Rubius sn... | → David Epstein has recruit... | - | Amber Tong | endpts.com... |
| 11.08.2016 | Protocol... | AbbVie’s decision to abrup... | - | John Carro... | endpts.com... |
| 22.07.2014 | MedImmune ... | MedImmune and Advaxis partner ... | - | - | cambridgen... |
| 01.11.2012 | Immunother... | Solution/product: It is develo... | - | - | medcitynew... |
| - | Immunother... | Company name: Advaxis. Indust... | - | - | medcitynew... |